rhThrombin Phase 3 Clinical Trial Progressing as Planned
SEATTLE, April 25 /PRNewswire-FirstCall/ -- ZymoGenetics, Inc. (Nasdaq:
ZGEN) announced today that Michael J. Dwyer will join the company in May as
Senior Vice President of Marketing and Sales and as a member of the
Executive Management Committee. Mr. Dwyer has nearly thirty years
experience in biologic and pharmaceutical marketing and sales, with
expertise in marketing execution, sales management and sales operations. He
will be responsible for continuing to build ZymoGenetics' sales, marketing
and operations/logistics team in preparation for anticipated launch of
recombinant human thrombin (rhThrombin) in late 2007.
"Mike's expertise in marketing and sales will be a tremendous asset to
ZymoGenetics as we prepare for the anticipated commercialization of
rhThrombin. His experience in building successful commercial operations
from the ground up and leading sales teams selling directly to hospitals
will be critical to a successful market launch," said Bruce L.A. Carter,
Ph.D., President and Chief Executive Officer of ZymoGenetics. "I'm also
pleased to report that our rhThrombin Phase 3 clinical trial and other
development programs are moving ahead as planned."
During his career, Mr. Dwyer has held positions in marketing and sales
at Bayer/Miles Inc. where he assisted in developing the introductory
strategy and product launch for Kogenate(R) (recombinant Factor VIII). As
Manager of Business Development and Marketing for Home Care and New
Products, Mr. Dwyer helped create marketing plans for biological products
in clinical trials and instituted uniform pricing and contractual
guidelines. Mr. Dwyer also served as Vice President of Marketing and
Materials Management for Caremark Therapeutic Services, a biopharmaceutical
provider of home therapies and services for individuals with chronic
disorders such as rheumatoid arthritis or hepatitis C.
More recently, Mr. Dwyer developed and executed strategic plans to
build new therapeutic markets and drive market shares for two product
launches. He devised launch strategies, designed operations and recruited
field sales forces for the U.S. launch of NovoSeven(R) and Norditropin(R).
Most recently, Mr. Dwyer was responsible for planning and implementing
selling strategies for an 850 person health care sales team in eight
regions as Vice President, Diabetes Sales for Novo Nordisk. In this
position, Mr. Dwyer led highly motivated sales teams and oversaw expansion
strategies, market penetration and key opinion leader development. He
improved operational efficiency by establishing a sales force automation
system. Mr. Dwyer holds an M.B.A. from Pepperdine University and a B.S.
from University of Dayton.
About ZymoGenetics
ZymoGenetics creates novel protein drugs with the potential to
significantly help patients fight their diseases. The Company is developing
a diverse pipeline of potential proprietary product candidates that are
moving into and through clinical development. These candidates span a wide
array of clinical opportunities that include bleeding, autoimmune diseases
and cancer. ZymoGenetics intends to commercialize these product candidates
through internal development, collaborations with partners, and
out-licensing of patents from its extensive patent portfolio. For further
information, visit http://www.zymogenetics.com.
This press release contains "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995. These
forward-looking statements are based on the current intent and expectations
of the management of ZymoGenetics. These statements are not guarantees of
future performance and involve risks and uncertainties that are difficult
to predict. ZymoGenetics' actual results and the timing and outcome of
events may differ materially from those expressed in or implied by the
forward-looking statements because of risks associated with our unproven
discovery strategy, preclinical and clinical development, regulatory
oversight, intellectual property claims and litigation and other risks
detailed in the company's public filings with the Securities and Exchange
Commission, including the company's Annual Report on Form 10-K for the year
ended December 31, 2005. Except as required by law, ZymoGenetics undertakes
no obligation to update any forward-looking or other statements in this
press release, whether as a result of new information, future events or
otherwise.
Contact
Investor Relations
John Calhoun, MD, MBA
Director, Corporate Communications & Investor Relations
206-442-6744
Media Relations
Susan W. Specht, MBA
Associate Director, Corporate Communications
206-442-6592
SOURCE ZymoGenetics, Inc.
 back to top
Related links:
http://www.zymogenetics.com/
CONTACT:
Investor Relations, John Calhoun, MD, MBA,
Director, Corporate Communications & Investor Relations,
+1-206-442-6744, or Media Relations, Susan W. Specht, MBA,
Associate Director, Corporate Communications, +1-206-442-6592,
both of ZymoGenetics, Inc.
|
